Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Castle Biosciences Reports Third Quarter 2025 Results (GlobeNewswire EN) +++ CASTLE BIOSCIENCES Aktie -3,00%

INSPIREMD Aktie

 >INSPIREMD Aktienkurs 
1.955 EUR    (Tradegate)
Ask: 2.02 EUR / 550 Stück
Bid: 1.89 EUR / 590 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
INSPIREMD Aktie über LYNX handeln
>INSPIREMD Performance
1 Woche: -4,4%
1 Monat: -10,2%
3 Monate: -24,5%
6 Monate: -18,1%
1 Jahr: -19,9%
laufendes Jahr: -28,3%
>INSPIREMD Aktie
Name:  INSPIREMD 1/18 DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45779A8466 / A3CMP3
Symbol/ Ticker:  II2 (Frankfurt)
Kürzel:  FRA:II2, ETR:II2, II2:GR
Index:  -
Webseite:  https://www.inspiremd.com..
Profil:  InspireMD Inc. is a leading medical device company..
>Volltext..
Marktkapitalisierung:  79.91 Mio. EUR
Unternehmenswert:  66.34 Mio. EUR
Umsatz:  6.12 Mio. EUR
EBITDA:  -36.37 Mio. EUR
Nettogewinn:  -35.87 Mio. EUR
Gewinn je Aktie:  -0.72 EUR
Schulden:  2.97 Mio. EUR
Liquide Mittel:  9.98 Mio. EUR
Operativer Cashflow:  -25.63 Mio. EUR
Bargeldquote:  2.14
Umsatzwachstum:  -2.16%
Gewinnwachstum:  -47.42%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  INSPIREMD
Letzte Datenerhebung:  03.11.25
>INSPIREMD Kennzahlen
Aktien/ Unternehmen:
Aktien: 41.72 Mio. St.
Frei handelbar: 61.25%
Leerverk. Aktien: -
Rückkaufquote: -3.52%
Mitarbeiter: 86
Umsatz/Mitarb.: 0.07 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 98.13%
Bewertung:
KGV: -
KGV lG: -
KUV: 16.2
KBV: 3.66
PEG-Ratio: -3.48
EV/EBITDA: -
Rentabilität:
Bruttomarge: 21.06%
Gewinnmarge: -585.64%
Operative Marge: -598.75%
Managementeffizenz:
Gesamtkaprendite: -92.99%
Eigenkaprendite: -123.51%
>INSPIREMD Peer Group

Es sind 597 Aktien bekannt.
 
03.11.25 - 17:09
InspireMD Q3 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.11.25 - 13:33
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer (GlobeNewswire EN)
 
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention....
08.10.25 - 14:03
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
MIAMI, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to three (3) new non-executive employees in the aggregate amount of 40,513 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of October 7, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4)....
25.09.25 - 22:06
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
MIAMI, Sept. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five (5) new non-executive employees in the aggregate amount of 88,324 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of September 24, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4)....
17.09.25 - 14:03
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors (GlobeNewswire EN)
 
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution....
27.08.25 - 15:03
InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)
 
MIAMI, Aug. 27, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10th at 10:00am Eastern Time (ET)....
05.08.25 - 18:36
InspireMD signals robust U.S. CGuard Prime launch progress and expands clinical pipeline following $58M capital infusion (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.25 - 14:18
InspireMD GAAP EPS of -$0.26, revenue of $1.78M misses by $0.02M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.25 - 14:03
InspireMD Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
 
--- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025....
04.08.25 - 17:12
InspireMD Q2 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.07.25 - 14:48
InspireMD raises $58M through combined financings; shares up (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.07.25 - 14:33
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors (GlobeNewswire EN)
 
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions....
22.07.25 - 13:03
InspireMD to Announce Second Quarter 2025 Financial Results (GlobeNewswire EN)
 
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights....
11.07.25 - 17:30
InspireMD Launches CGuard Prime Carotid Stent System in the U.S. (Zacks)
 
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention....
24.06.25 - 22:09
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke (GlobeNewswire EN)
 
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States....
13.06.25 - 15:03
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke (GlobeNewswire EN)
 
MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS....
03.06.25 - 22:36
InspireMD appoints Michael Lawless CFO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.06.25 - 22:06
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer (GlobeNewswire EN)
 
Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)...
09.05.25 - 18:12
InspireMD outlines Q3 2025 FDA approval target for CGuard Prime (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 16:00
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
 
InspireMD (NSPR) delivered earnings and revenue surprises of -29.41% and 9.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die deutschen politischen Schriftsteller, nicht an Geist fehlt es ihnen, aber an Mut. - Ludwig Börne
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!